Eli Lilly and Boehringer Ingelheim's Trajenta has been found to demonstrate no increased cardiovascular risk compared to glimepiride in adults with type II diabetes and cardiovascular risk.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.